Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
JCI Insight ; 9(10)2024 Apr 11.
Artigo em Inglês | MEDLINE | ID: mdl-38775152

RESUMO

Children with perinatally acquired HIV (PHIV) have special vaccination needs, as they make suboptimal immune responses. Here, we evaluated safety and immunogenicity of 2 doses of 4-component group B meningococcal vaccine in antiretroviral therapy-treated children with PHIV and healthy controls (HCs). Assessments included the standard human serum bactericidal antibody (hSBA) assay and measurement of IgG titers against capsular group B Neisseria meningitidis antigens (fHbp, NHBA, NadA). The B cell compartment and vaccine-induced antigen-specific (fHbp+) B cells were investigated by flow cytometry, and gene expression was investigated by multiplexed real-time PCR. A good safety and immunogenicity profile was shown in both groups; however, PHIV demonstrated a reduced immunogenicity compared with HCs. Additionally, PHIV showed a reduced frequency of fHbp+ and an altered B cell subset distribution, with higher fHbp+ frequency in activated memory and tissue-like memory B cells. Gene expression analyses on these cells revealed distinct mechanisms between PHIV and HC seroconverters. Overall, these data suggest that PHIV presents a diverse immune signature following vaccination. The impact of such perturbation on long-term maintenance of vaccine-induced immunity should be further evaluated in vulnerable populations, such as people with PHIV.


Assuntos
Infecções por HIV , Vacinas Meningocócicas , Humanos , Infecções por HIV/imunologia , Masculino , Feminino , Criança , Vacinas Meningocócicas/imunologia , Vacinas Meningocócicas/administração & dosagem , Pré-Escolar , Infecções Meningocócicas/imunologia , Infecções Meningocócicas/prevenção & controle , Anticorpos Antibacterianos/imunologia , Anticorpos Antibacterianos/sangue , Linfócitos B/imunologia , Transmissão Vertical de Doenças Infecciosas/prevenção & controle , Imunogenicidade da Vacina , Imunoglobulina G/imunologia , Imunoglobulina G/sangue
2.
Clin Exp Med ; 24(1): 72, 2024 Apr 10.
Artigo em Inglês | MEDLINE | ID: mdl-38598028

RESUMO

We aim at investigating the association between subclinical autoimmunity and immune-related adverse events (irAEs) in a cohort of patients treated by immune checkpoint inhibitors for solid metastatic cancer. In the context of an oncology/rheumatology outpatient clinic, we evaluated patients treated with anti-PD-1 or anti-PD-L1. Before treatment, each patient underwent a physical evaluation and a blood sample to identify the presence of a set of autoantibodies. Indeed, all the patients were followed during treatment to identify irAEs and to assess the association with autoantibodies. Fifty-one patients (M/F 16/35; median age 70 years, IQR 16.5) were evaluated; 34.8% of patients showed ANA positivity, 6.5% ENA positivity (anti-SSA), 4.3% Ratest positivity, and 2.1% (one patient) ACPA positivity. During a median period of 21 months (IQR 38.75), 39.2% of patients developed irAEs. Musculo-skeletal manifestations, in particular arthritis, were the most frequent. We found a significant association between the positivity for ANA and the development of irAES (p = 0.03, RR 2.01, 95% CI 1.03-3.92). Furthermore, the progression-free survival was significantly longer in patients developing irAEs compared to those who are not experiencing these events (p = 0.007). This study underlines the potential role of ANA positivity as a predictive biomarker for the development of irAEs.


Assuntos
Anticorpos Antinucleares , Artrite , Humanos , Idoso , Inibidores de Checkpoint Imunológico/efeitos adversos , Autoanticorpos , Autoimunidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA